Loading
A phase 1/2 trial of Pembrolizumab, Carboplatin and Oxaliplatin in advanced solid tumours, run by Astellas Pharma Global Development, Inc., now recruiting.
A Study of ASP388B Given by Itself and With Standard Therapies in Participants With Solid Tumors is a phase 1/2 interventional study registered as NCT07730021 by Astellas Pharma Global Development, Inc., with 392 participants planned, started 2026-09-02 and due to reach its primary completion in 2030-02-28. Interventions recorded: ASP388B, Pembrolizumab, Carboplatin, Oxaliplatin and 5-fluorouracil.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Astellas, Carboplatin, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Astellas, Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Shares Astellas, Oxaliplatin, Pembrolizumab and the tag pipeline.
Shares Oxaliplatin, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread), Pembrolizumab and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/